Breast cancer care in Latin America and the Caribbean (LAC)
Eduardo Cazap(Facultad Latinoamericana de Ciencias Argentina), Carlos Vallejos, E. Mickiewicz(University of Chicago), Carlos Garbino(Latin American and Caribbean Society of Medical Oncology), Gilberto Schwartsmann(Universidade Luterana do Brasil), Francisco J. Orlandi(Latin American and Caribbean Society of Medical Oncology), A. Guercovich(Latin American and Caribbean Society of Medical Oncology), R. Contreras Chacon(Universidad de Buenos Aires), Antônio C. Buzaid(Johns Hopkins University)
Cited by 3
Related Papers
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Activity of Exemestane in Metastatic Breast Cancer After Failure of Nonsteroidal Aromatase Inhibitors: A Phase II Trial
|Journal of Clinical Oncology|2000|318